Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 282,568 shares of the company’s stock, valued at approximately $1,175,000. Walleye Capital LLC owned approximately 0.23% of Aquestive Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. NewEdge Advisors LLC bought a new position in shares of Aquestive Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets increased its position in shares of Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth about $33,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the 1st quarter worth about $42,000. Finally, ADAR1 Capital Management LLC lifted its position in Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Insider Transactions at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at approximately $125,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $8.50.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $4.25 on Friday. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55. The company has a market capitalization of $533.43 million, a PE ratio of -6.54 and a beta of 1.49. The business has a fifty day moving average price of $4.14 and a two-hundred day moving average price of $4.08.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. Sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.